{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:45:13Z","timestamp":1791297913280,"version":"4.1.0"},"reference-count":50,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:p>Several lines of evidence, including the recent discovery of novel susceptibility genes, point out an important role for the mammalian target of rapamycin (mTOR) signaling pathway in the development of pheochromocytoma. Analyzing a set of pheochromocytomas from patients with different genetic backgrounds, we observed and confirmed a significant overexpression of key mTOR complex (mTORC) signaling mediators. Using selective ATP-competitive inhibitors targeting both mTORC1 and mTORC2, we significantly arrested the in vitro cell proliferation and blocked migration of pheochromocytoma cells as a result of the pharmacological suppression of the Akt\/mTOR signaling pathway. Moreover, AZD8055, a selective ATP-competitive dual mTORC1\/2 small molecular inhibitor, significantly reduced the tumor burden in a model of metastatic pheochromocytoma using female athymic nude mice. This study suggests that targeting both mTORC1 and mTORC2 is a potentially rewarding strategy and supports the application of selective inhibitors in combinatorial drug regimens for metastatic pheochromocytoma.<\/jats:p>","DOI":"10.1210\/en.2012-1854","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T07:20:16Z","timestamp":1357888816000},"page":"646-655","source":"Crossref","is-referenced-by-count":43,"title":["Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice"],"prefix":"10.1210","volume":"154","author":[{"given":"Alessio","family":"Giubellino","sequence":"first","affiliation":[{"name":"Program in Reproductive and Adult Endocrinology (A.G., P.B., H.T., K.P.),Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bullova","sequence":"first","affiliation":[{"name":"Program in Reproductive and Adult Endocrinology (A.G., P.B., H.T., K.P.),Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"first","affiliation":[{"name":"Department of Endocrinology (S.N., A.B.G.),William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Turkova","sequence":"first","affiliation":[{"name":"Program in Reproductive and Adult Endocrinology (A.G., P.B., H.T., K.P.),Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Powers","sequence":"first","affiliation":[{"name":"Department of Pathology (J.F.P., A.S.T.), Tufts Medical Center, Boston, Massachusetts 02111;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Liu","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute (Q.L.), Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Guichard","sequence":"first","affiliation":[{"name":"AstraZeneca (S.G.), Oncology iMed, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Tischler","sequence":"first","affiliation":[{"name":"Department of Pathology (J.F.P., A.S.T.), Tufts Medical Center, Boston, Massachusetts 02111;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Grossman","sequence":"first","affiliation":[{"name":"Department of Endocrinology (S.N., A.B.G.),William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom"},{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism (A.B.G.), Churchill Hospital, University of Oxford, Headington, Oxford OX3 7LE, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"first","affiliation":[{"name":"Program in Reproductive and Adult Endocrinology (A.G., P.B., H.T., K.P.),Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"2020071612235455000_B1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.5858\/2008-132-1272-PAEPU","article-title":"Pheochromocytoma and extra-adrenal paraganglioma: updates","volume":"132","author":"Tischler","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"2020071612235455000_B2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-0029-1231025","article-title":"Treatment of malignant pheochromocytoma","volume":"41","author":"Adjalle","year":"2009","journal-title":"Horm Metab Res"},{"key":"2020071612235455000_B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12022-012-9199-6","article-title":"Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies","volume":"23","author":"Nolting","year":"2012","journal-title":"Endocr Pathol"},{"key":"2020071612235455000_B4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1677\/erc.1.01116","article-title":"Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues","volume":"12","author":"Kaltsas","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2020071612235455000_B5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612235455000_B6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"2020071612235455000_B7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"2020071612235455000_B8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2020071612235455000_B9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"Wander","year":"2011","journal-title":"J Clin Invest"},{"key":"2020071612235455000_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"2020071612235455000_B11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"2020071612235455000_B12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2011.47.10.1673555","article-title":"Current treatment options for neuroendocrine tumors","volume":"47","author":"Horsch","year":"2011","journal-title":"Drugs Today (Barc)"},{"key":"2020071612235455000_B13","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-10-3962","article-title":"Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis","volume":"71","author":"Nardella","year":"2011","journal-title":"Cancer Res"},{"key":"2020071612235455000_B14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"key":"2020071612235455000_B15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res"},{"key":"2020071612235455000_B16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2020071612235455000_B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3940(98)00936-7","article-title":"Discordant effects of rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells","volume":"259","author":"Powers","year":"1999","journal-title":"Neurosci Lett"},{"key":"2020071612235455000_B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"2020071612235455000_B19","doi-asserted-by":"crossref","first-page":"40406","DOI":"10.1074\/jbc.M508361200","article-title":"mTOR.RICTOR is the Ser473 kinase for Akt\/protein kinase B in 3T3-L1 adipocytes","volume":"280","author":"Hresko","year":"2005","journal-title":"J Biol Chem"},{"key":"2020071612235455000_B20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.4161\/cc.6.15.4521","article-title":"ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice","volume":"6","author":"Lai","year":"2007","journal-title":"Cell Cycle"},{"key":"2020071612235455000_B21","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1\u03b1 and 2\u03b1 on mTORC1 and mTORC2","volume":"283","author":"Toschi","year":"2008","journal-title":"J Biol Chem"},{"key":"2020071612235455000_B22","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1210\/jc.2006-0920","article-title":"Expression of HIF-1\u03b1, HIF-2\u03b1 (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations","volume":"91","author":"Pollard","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612235455000_B23","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1158\/0008-5472.CAN-07-5580","article-title":"Cells silenced for SDHB expression display characteristic features of the tumor phenotype","volume":"68","author":"Cervera","year":"2008","journal-title":"Cancer Res"},{"key":"2020071612235455000_B24","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/me.2010-0256","article-title":"Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas","volume":"24","author":"Lopez-Jimenez","year":"2010","journal-title":"Mol Endocrinol"},{"key":"2020071612235455000_B25","doi-asserted-by":"crossref","first-page":"e7094","DOI":"10.1371\/journal.pone.0007094","article-title":"The Warburg effect is genetically determined in inherited pheochromocytomas","volume":"4","author":"Favier","year":"2009","journal-title":"PLoS One"},{"key":"2020071612235455000_B26","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J Biol Chem"},{"key":"2020071612235455000_B27","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1021\/jm101144f","article-title":"Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer","volume":"53","author":"Liu","year":"2010","journal-title":"J Med Chem"},{"key":"2020071612235455000_B28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"2020071612235455000_B29","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"key":"2020071612235455000_B30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.beem.2010.04.001","article-title":"SDH-related pheochromocytoma and paraganglioma","volume":"24","author":"Kantorovich","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2020071612235455000_B31","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1158\/1078-0432.CCR-09-1237","article-title":"Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients","volume":"15","author":"Erlic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2020071612235455000_B32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00441-010-0965-9","article-title":"Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla","volume":"340","author":"Fliedner","year":"2010","journal-title":"Cell Tissue Res"},{"key":"2020071612235455000_B33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1177\/40.7.1351491","article-title":"Immunocytochemical analysis of chromaffin cell proliferation in vitro","volume":"40","author":"Tischler","year":"1992","journal-title":"J Histochem Cytochem"},{"key":"2020071612235455000_B34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10585-009-9236-0","article-title":"Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature","volume":"26","author":"Martiniova","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"2020071612235455000_B35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2011.10.019","article-title":"Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging","volume":"316","author":"Giubellino","year":"2012","journal-title":"Cancer Lett"},{"key":"2020071612235455000_B36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan","year":"2011","journal-title":"Cancer Control"},{"key":"2020071612235455000_B37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4149\/endo_2011_02_65","article-title":"Phaeochromocytoma: a catecholamine and oxidative stress disorder","volume":"45","author":"Pacak","year":"2011","journal-title":"Endocr Regul"},{"key":"2020071612235455000_B38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1055\/s-0029-1214381","article-title":"Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies","volume":"41","author":"Santarpia","year":"2009","journal-title":"Horm Metab Res"},{"key":"2020071612235455000_B39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrd3181","article-title":"Personalized medicine in oncology: the future is now","volume":"9","author":"Schilsky","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2020071612235455000_B40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/er.2009-0031","article-title":"The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors","volume":"31","author":"Ye","year":"2010","journal-title":"Endocr Rev"},{"key":"2020071612235455000_B41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1677\/ERC-09-0118","article-title":"Microarray analysis reveals differential expression of benign and malignant pheochromocytoma","volume":"17","author":"Waldmann","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2020071612235455000_B42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1\u03b1 regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"key":"2020071612235455000_B43","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"2020071612235455000_B44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/EJE-11-0497","article-title":"The genetics of phaeochromocytoma: using clinical features to guide genetic testing","volume":"166","author":"Jafri","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2020071612235455000_B45","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/en.2011-0052","article-title":"The busy road to pheochromocytomas and paragangliomas has a new member, TMEM127","volume":"152","author":"Jiang","year":"2011","journal-title":"Endocrinology"},{"key":"2020071612235455000_B46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1055\/s-0029-1215590","article-title":"Pheochromocytomas: from genetic diversity to new paradigms","volume":"41","author":"Qin","year":"2009","journal-title":"Horm Metab Res"},{"key":"2020071612235455000_B47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"2020071612235455000_B48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/84879","article-title":"Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse","volume":"27","author":"Di Cristofano","year":"2001","journal-title":"Nat Genet"},{"key":"2020071612235455000_B49","first-page":"883","article-title":"Animal models of pheochromocytoma","volume":"19","author":"Tischler","year":"2004","journal-title":"Histol Histopathol"},{"key":"2020071612235455000_B50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/154\/2\/646\/8979890\/endo0646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/154\/2\/646\/8979890\/endo0646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T19:08:05Z","timestamp":1644088085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/154\/2\/646\/2423313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2012-1854","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}